22.418 articles found

Proteomic analysis of the neuroprotective mechanisms of acupuncture treatment in a Parkinson's disease mouse model.

Jeon S, Kim YJ, Kim ST, Moon W, Chae Y, Kang M, Chung MY, Lee H, Hong MS, Chung JH, Joh TH, Lee H, Park HJ.

Proteomics · 2008-11-01

DOI: 10.1002/pmic.200700955PMID: 18942673

Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease.

Zhang X, Tellew JE, Luo Z, Moorjani M, Lin E, Lanier MC, Chen Y, Williams JP, Saunders J, Lechner SM, Markison S, Joswig T, Petroski R, Piercey J, Kargo W, Malany S, Santos M, Gross RS, Wen J, Jalali K, O'Brien Z, Stotz CE, Crespo MI, Díaz JL, Slee DH.

J Med Chem · 2008-11-01

DOI: 10.1021/jm800851uPMID: 18947224

Diagnosis and treatment of depression comorbid with neurologic disorders.

Raskind MA.

Am J Med · 2008-11-01

DOI: 10.1016/j.amjmed.2008.09.011PMID: 18954590

Use of the new levodopa agent Stalevo (levodopa/carbidopa/entacapone) in the treatment of Parkinson's disease in out-patient clinical practice (the START-M open trial).

Boiko AN, Batysheva TT, Minaeva NG, Babina LA, Vdovichenko TV, Zhuravleva EY, Shikhkerimov RK, Malykhina EA, Khozova AA, Zaitsev KA, Kostenko EV.

Neurosci Behav Physiol · 2008-11-01

DOI: 10.1007/s11055-008-9085-3PMID: 18975095

Activation of the proopiomelanocortin gene with ketoconazole as a treatment for Parkinson's disease: a new hypothesis.

Halabe Bucay A.

Ann N Y Acad Sci · 2008-11-01

DOI: 10.1196/annals.1418.013PMID: 19076380

[Treatment of Parkinson's disease at present and in the future].

Kuzuhara S.

Rinsho Shinkeigaku · 2008-11-01

DOI: 10.5692/clinicalneurol.48.835PMID: 19198095

[Therapy of Parkinson's disease--up to date].

Murata M.

Rinsho Shinkeigaku · 2008-11-01

DOI: 10.5692/clinicalneurol.48.986PMID: 19198140

Botulinum toxin type A and type B for sialorrhoea in Parkinson's disease: a case for switching therapy?

Santamato A, Panza F, Solfrizzi V, Frisardi V, Ranieri M, Fiore P.

J Rehabil Med · 2008-11-01

DOI: 10.2340/16501977-0257PMID: 19242630

Network biomarkers for the diagnosis and treatment of movement disorders.

Poston KL, Eidelberg D.

Neurobiol Dis · 2008-11-01

DOI: 10.1016/j.nbd.2008.09.026PMID: 19013242

A CONTROLLED-RELEASE PARTIAL GLYCINE AGONIST COMPOSITION FOR USE WITH LEVODOPA IN PARKINSON'S DISEASE AND METHOD OF USE

FIORENTINI ROBERTO.

· 2008-10-31

BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson's disease.

Foltynie T, Cheeran B, Williams-Gray CH, Edwards MJ, Schneider SA, Weinberger D, Rothwell JC, Barker RA, Bhatia KP.

J Neurol Neurosurg Psychiatry · 2008-10-31

DOI: 10.1136/jnnp.2008.154294PMID: 18977816

Changes in psychomotor effects of L-dopa and methylphenidate after sustained dopaminergic therapy in Parkinson's disease.

Evans AH, Lawrence AD, Lees AJ.

J Neurol Neurosurg Psychiatry · 2008-10-31

DOI: 10.1136/jnnp.2006.108993PMID: 18977820